Olsalazine (Aminosalicylate)
โ ๏ธ Renal monitoring is essential:
Check serum creatinine before starting olsalazine, then:
โ Every 3 months in year 1
โ Every 6 months for the next 4 years
โ Annually after 5 years of treatment.
- ๐น Used mainly to treat ulcerative colitis.
- ๐ Systemic absorption is minimal โ drug remains largely in colonic lumen.
- ๐ฉโโ๏ธ Considered when mesalazine is not tolerated or when colonic delivery is preferred.
โ๏ธ Mode of Action
- ๐งช Olsalazine itself is relatively inert.
- ๐ก Poorly absorbed in the small intestine โ reaches the colon intact.
- ๐ฆ In the colon, gut bacteria split olsalazine into two molecules of 5-ASA (mesalazine).
- ๐ฅ 5-ASA is the active anti-inflammatory agent, inhibiting prostaglandins, leukotrienes, and cytokines โ reduced local inflammation.
- ๐ Similar mechanism to sulphasalazine but without a sulphapyridine carrier (less systemic toxicity).
๐ฏ Indications
- ๐ฅ Mild to moderate ulcerative colitis (induction & maintenance).
- ๐ Best taken after meals to reduce risk of diarrhoea.
๐ Dose
- โก๏ธ Acute flare: 1โ3 g/day PO in divided doses.
- โก๏ธ Maintenance: 500 mg PO BD.
๐ Interactions
- ๐ See BNF for full list (monitor renal toxicity risk if combined with other nephrotoxic drugs such as NSAIDs).
โ Contraindications
- ๐ซ Avoid in pregnancy & lactation unless specialist advice obtained.
- โ ๏ธ Use with caution in renal impairment (monitor function regularly).
โ ๏ธ Side Effects
- ๐ฉ Watery diarrhoea (dose-limiting in some patients).
- ๐๏ธ Blurred vision (rare).
- โค๏ธ Palpitations.
- Rare: rash, arthralgia, and blood dyscrasias (monitor if unexplained fever or bruising).
๐ References